Xeris Biopharma Holdings, Inc. (XERS) · Oct 14, 2026 · Other events

Xeris patent lawsuit targets generic Keveyis challengers

Patent litigation — Two infringement actions tied to newly granted ’502 patent

Xeris filed patent infringement lawsuits over Keveyis, seeking to block generic dichlorphenamide competition—but the commercial payoff remains uncertain.

Xeris is a commercial-stage specialty biopharma building growth around Recorlev and Gvoke while Keveyis remains a meaningful, mature contributor; Keveyis generated $47.6 million in 2025 revenue, down from $49.5 million in 2024. The filing adds a defensive legal step around a mature product. Xeris has now sued two groups of potential generic competitors after receiving a new patent covering Keveyis. 〔0〕 That could help preserve Keveyis revenue if the patent survives and the defendants are blocked or delayed, but the filing creates no immediate sales, exclusivity ruling, or cash inflow.

The strategic signal is useful, but the outcome is unresolved. The complaints seek injunctions and damages, yet they only allege infringement; they do not establish that the patent will be upheld or that generic entry will ultimately be prevented. 〔1〕 Because the earlier patent-development direction was already public, the lawsuits are the new step; the economic value depends on subsequent court decisions rather than this announcement itself.

Bottom line: This strengthens Xeris’s effort to defend Keveyis, but it is an uncertain legal process rather than an immediate business win. The event matters mainly because Keveyis is still a sizable revenue stream, even as the company’s growth story increasingly rests on Recorlev and Gvoke.

What to watch next

Court proceedings over the ’502 patent

Original filing on SEC EDGAR

More Xeris Biopharma Holdings, Inc. news

Xeris patent lawsuit targets generic Keveyis challengers | XERS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.